05:19 AM EDT, 10/20/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Sunday that its ivonescimab product candidate, in combination with chemotherapy, demonstrated a "statistically significant improvement" in progression-free survival compared with tislelizumab plus chemotherapy in a phase 3 study of the combination therapy in advanced squamous non-small cell lung cancer.

The company said the findings were based on planned interim analysis of the study's primary endpoint of progression-free survival, while data for overall survival will be evaluated in the future.

Ivonescimab also demonstrated an "acceptable and manageable" safety profile in the study, Summit Therapeutics ( SMMT ) said.

The phase 3 study was conducted in China and the company said it is currently enrolling patients for a multiregional phase 3 trial that will evaluate the ivonescimab and chemotherapy combination, compared with pembrolizumab plus chemotherapy, in patients with first-line metastatic, squamous and non-squamous non-small cell lung cancer.

Summit Therapeutics ( SMMT ) expects to complete enrollment for the trial's squamous group in H1 2026 and the non-squamous group in H2, according to the statement.